Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19792368 | 0.86 | DGAT1 (0.46) | LPLLIPGIRAK4DGAT1 | |
| SCHEMBL26653814 | 0.74 | DGAT1 (0.39) | LPLLIPGIRAK4DGAT1HIF1A | |
| SCHEMBL30657968 | 0.74 | DGAT1 (0.39) | LPLLIPGIRAK4DGAT1HIF1A | |
| SCHEMBL29897337 | 0.73 | LPL (0.47) | LPLLIPGIRAK4DGAT1SNCA | |
| SCHEMBL19792374 | 0.73 | MEN1 (0.37) | — | |
| SCHEMBL9941723 | 0.73 | LPL (0.47) | LPLLIPGIRAK4DGAT1SNCA | |
| SCHEMBL29644319 | 0.73 | LPL (0.62) | LPLLIPGIRAK4HIF1ASNCA | |
| SCHEMBL1293460 | 0.73 | LPL (0.62) | LPLLIPGIRAK4HIF1ASNCA | |
| SCHEMBL12654466 | 0.72 | LPL (0.54) | LPLLIPGIRAK4HIF1ACSF1R | |
| SCHEMBL7600427 | 0.71 | LPL (0.55) | LPLLIPGIRAK4DGAT1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241573-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| WO-2018015879-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241573-A1 | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | PSEN1, CPT1A, IRS1 | LPL 2339/4885LIPG 2211/4885IRAK4 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.